{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-237077","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2023-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.811237+00:00","generated_at":"2026-06-10T13:52:37.561112+00:00","sec_items":["1.01","2.01","9.01","5.02","4.01","3.03","5.03","5.01","5.05","5.06"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"First Light Acquisition Group completes business combination with Calidi Biotherapeutics, begins trading as CLDI","bullets":["Business combination closed Sept 12, 2023; FLAG renamed Calidi Biotherapeutics, Inc., trading under CLDI and CLDI WS.","Aggregate merger consideration ~$250M plus $23.8M net debt adjustment; 27.4M shares issued to Calidi holders.","Up to 18M escalation shares earnable if CLDI hits $12/$14/$16/$18 price hurdles over 20 of 30 days.","2.7M FLAG public shares redeemed for ~$28.2M; post-merger 35.9M shares outstanding.","Ownership: Calidi holders 77.4%, FLAG insiders 15.4%, public 7.2%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-237077","json":"https://secwatch.observer/filing/0001193125-23-237077.json","markdown":"https://secwatch.observer/filing/0001193125-23-237077.md","text":"https://secwatch.observer/filing/0001193125-23-237077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/0001193125-23-237077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/d894152d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T13:52:37.561112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32f365e9b55a49d8402e844ae70acfb6a1968ada","claim":"Calidi Biotherapeutics, Inc.: Adopted amended and restated bylaws.","evidence_excerpt":"adopted the amended and restated bylaws (the “Amended and Restated Bylaws”), which became effective at Closing","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/0001193125-23-237077-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"580a5c9411052ce7728f32d4ce6629c095e969cc","claim":"Calidi Biotherapeutics, Inc.: Adopted a new Code of Business Conduct and Ethics.","evidence_excerpt":"the Board adopted a new Code of Business Conduct and Ethics applicable to all of the Company’s directors and employees","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/0001193125-23-237077-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"}],"fact_type":"governance_change"},{"claim_id":"c487512609cdefaaad34fb1df6e4dfd84ff279cc","claim":"Calidi Biotherapeutics, Inc.: Amended and restated certificate of incorporation via Second Amended and Restated Certificate of Incorporation.","evidence_excerpt":"the Company amended and restated its certificate of incorporation pursuant to the filing of the Second Amended and Restated Certificate of Incorporation (“Second Amended and Restated Certificate of Incorporation”) with the Secretary of State of the State of Delaware (“Delaware Secretary of State”) which became effective upon acceptance of filing by the Delaware Secretary of State","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/0001193125-23-237077-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"c9e7c060dc85b14886ec1717ef078418bc76d245","claim":"Calidi Biotherapeutics, Inc. underwent a change of control involving First Light Acquisition Group, Inc. (closed 2023-09-12).","evidence_excerpt":"Business Combination On September 12, 2023, First Light Acquisition Group, Inc., a Delaware corporation (“FLAG”) consummated a series of transactions that resulted in the merger of FLAG Merger Sub Inc., a Nevada corporation, a wholly-owned subsidiary of FLAG (“Merger Sub”) and Calidi Biotherapeutics, Inc., a Nevada corporation (“Calidi”) pursuant to the Agreement and Plan of Merger","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/0001193125-23-237077-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"First Light Acquisition Group, Inc."},{"label":"Closing","value":"2023-09-12"}],"fact_type":"ma_transaction"},{"claim_id":"4c4a8d264f23579256bba655546e91601e94c75f","claim":"Calidi Biotherapeutics, Inc. entered into Share and Warrant Cancellation Agreement with Sponsor and Metric.","evidence_excerpt":"effective as of the Closing Date, the Company entered into the Share and Warrant Cancellation Agreement with the Sponsor and Metric.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/0001193125-23-237077-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Sponsor and Metric"}],"fact_type":"material_agreement"},{"claim_id":"6032fb476768e71ffcacf0a606c98004422d2a70","claim":"Calidi Biotherapeutics, Inc. entered into Amended and Restated Registration Rights Agreement with Sponsor, Metric, Allan Camaisa, Scott Leftwich and certain other parties (effective 2023-09-12).","evidence_excerpt":"the Company, the Sponsor, Metric, Allan Camaisa, Scott Leftwich and certain other parties thereto entered into the Registration Rights Agreement on September 12, 2023.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/0001193125-23-237077-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Sponsor, Metric, Allan Camaisa, Scott Leftwich and certain other parties"},{"label":"Effective","value":"2023-09-12"}],"fact_type":"material_agreement"},{"claim_id":"949f10ec36face0c564e4bedd539d6019de2b4c2","claim":"Calidi Biotherapeutics, Inc. amended Amendment of Warrant Agreement with Continental Stock Transfer & Trust Company and Equiniti Trust Company, LLC.","evidence_excerpt":"On the Closing Date, the Company entered into the Amendment of Warrant Agreement with Continental Stock Transfer & Trust Company and Equiniti Trust Company, LLC, to engage Equiniti Trust Company, LLC as the new Warrant Agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/0001193125-23-237077-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Continental Stock Transfer & Trust Company and Equiniti Trust Company, LLC"}],"fact_type":"material_agreement"},{"claim_id":"a1ac8e4407569e5ea53185a9d07d03f240dc4a97","claim":"Calidi Biotherapeutics, Inc. entered into Escrow Services Agreement with Equiniti Trust Company, LLC (effective 2023-09-12).","evidence_excerpt":"Concurrently with the Closing, the Company and Equiniti Trust Company, LLC, as escrow agent (the “Escrow Agent”), entered into an Escrow Services Agreement (“Escrow Agreement”), effective as of September 12, 2023","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/0001193125-23-237077-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Equiniti Trust Company, LLC"},{"label":"Effective","value":"2023-09-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}